ProfileGDS5678 / 1451007_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 17% 17% 17% 17% 18% 16% 17% 17% 17% 17% 17% 17% 17% 17% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4299917
GSM967853U87-EV human glioblastoma xenograft - Control 22.4148717
GSM967854U87-EV human glioblastoma xenograft - Control 32.4151417
GSM967855U87-EV human glioblastoma xenograft - Control 42.3692217
GSM967856U87-EV human glioblastoma xenograft - Control 52.3916418
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4497316
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.434517
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.3927217
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3861717
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4037917
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.3976617
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.3889217
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.408817
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4026917